Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor supportClinical
First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and lung fluid showed
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and
Previously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution
ROBBIN addresses
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features
In the overall BOT+BAL treated population, median
Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival
In a
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy
Median overall survival of 12.3 months in a heavily pretreated population with poor
